CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients
Abstract High inter-individual variability in tacrolimus clearance is attributed to genetic polymorphisms of CYP3A enzymes. However, due to CYP3A phenoconversion induced by non-genetic factors, continuous changes in tacrolimus-metabolizing capacity entail frequent dose-refinement for optimal immunos...
Guardado en:
Autores principales: | Máté Déri, Zsófia Szakál-Tóth, Ferenc Fekete, Katalin Mangó, Evelyn Incze, Annamária Minus, Béla Merkely, Balázs Sax, Katalin Monostory |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/432193eb97624b7c9b53b30747e53717 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects
por: Ferenc Fekete, et al.
Publicado: (2021) -
Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients
por: Jae Hyun Kim, et al.
Publicado: (2019) -
Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients
por: Cheng F, et al.
Publicado: (2021) -
Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients
por: Lekshmy Srinivas, et al.
Publicado: (2021) -
Association between medication adherence and intrapatient variability in tacrolimus concentration among stable kidney transplant recipients
por: Hyunmin Ko, et al.
Publicado: (2021)